Bristol Myers Squibb Co.
- BMY ยท NYSE
- Pharmaceutical Preparations
- Princeton, NJ
- 32,500 employees
- CIK 0000014272
Updated from SEC filings through
Top things to know
Executives
- Christopher S. Boerner Chief Executive Officer 4, 2026-03-12
- David Elkins V. EVP, Chief Financial Officer 4, 2026-04-02
- David V. Elkins Chief Financial Officer (Principal Financial Officer) 10-K, 2026-02-11
- Adam Lenkowsky EVP, Chief Commercial Officer 4, 2026-05-05
- Karin Shanahan EVP, Chief Supply Chain & Ops 4, 2026-04-02
- Lynelle Hoch President, Cell Therapy Org. 4, 2026-03-12
Bristol Myers Squibb Co is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Princeton, NJ. It trades as BMY on NYSE. Revenue was $48.2B in the fiscal year ending December 31, 2025, -0.2% from the year before. It reported about 32,500 employees. Christopher S. Boerner is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.2B 10-K, 2026-02-11 | $48.3B 10-K, 2026-02-11 | $45.0B 10-K, 2026-02-11 | $46.2B 10-K, 2025-02-12 | $46.4B 10-K, 2024-02-13 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $7.3B 10-K, 2026-02-11 | $8.4B 10-K, 2026-02-11 | $7.8B 10-K, 2026-02-11 | $7.8B 10-K, 2025-02-12 | $7.7B 10-K, 2024-02-13 |
| Net income | $7.1B 10-K, 2026-02-11 | -$8.9B 10-K, 2026-02-11 | $8.0B 10-K, 2026-02-11 | $6.3B 10-K, 2025-02-12 | $7.0B 10-K, 2024-02-13 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 4, 2026-03-12 |
| David Elkins V. | EVP, Chief Financial Officer | 4, 2026-04-02 |
| David V. Elkins EVP & Chief Financial Officer at Bristol Myers Squibb | Chief Financial Officer (Principal Financial Officer) | 10-K, 2026-02-11 |
| Adam Lenkowsky Advancing patient care as Executive Vice President, Chief Commercial Officer at Bristol Myers Squibb | EVP, Chief Commercial Officer | 4, 2026-05-05 |
| Karin Shanahan EVP, Chief Supply Chain & Operations Officer | EVP, Chief Supply Chain & Ops | 4, 2026-04-02 |
| Cristian Massacesi, M.D. Executive Vice President, Chief Medical Officer & Head of Development at Bristol Myers Squibb | Named in proxy bio: EVP and Chief Medical Officer, Head of Development | DEF 14A, 2026-03-25 |
| Greg Meyers | Named in proxy bio: EVP and Chief Digital & Technology Officer | DEF 14A, 2026-03-25 |
| Samit Hirawat, M.D. | Named in proxy bio: Former EVP and Chief Medical Officer, Head of Development | DEF 14A, 2026-03-25 |
| Lynelle Hoch Unlocking the Promise of Cell Therapy as the President of the Cell Therapy Organization and Member of Bristol Myers Squibb Leadership Team | President, Cell Therapy Org. | 4, 2026-03-12 |
| Robert M. Plenge EVP, Chief Research Officer | EVP, Chief Research Officer | 4, 2026-03-12 |
| Benjamin Hickey | President, RayzeBio Org. | 4, 2026-03-12 |
| Ahn Amanda Poole | EVP, Chief People Officer | 4, 2026-03-12 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 4, 2026-03-12 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 4, 2026-03-12 |
| Bartie Wendy Short | EVP, Corporate Affairs | 4, 2026-09-03 |
| Phil M. Holzer | SVP and Controller | 4, 2026-08-26 |
What Bristol Myers Squibb Co does
Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 2.04 billion (as of October 21, 2026) | 10-Q, October 29, 2026 |
|---|---|---|
| Public float | $94.2B (as of June 30, 2025) | 10-K, February 11, 2026 |
| Latest proxy statement | Meeting May 5, 2026 (filed March 25, 2026) | DEF 14A, March 25, 2026 |
| Auditor | Deloitte & Touche LLP (Morristown, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 5, 2026 | Julia A. Haller Director | Sale | 3,800 | $241K | Form 4, November 6, 2026 |
| September 9, 2026 | Cristian Massacesi EVP,Chief Med Offr,Head of Dev | Sale | 6,249 | $403K | Form 4, September 10, 2026 |
| August 25, 2026 | Phil M. Holzer SVP and Controller | Sale | 500 | $34K | Form 4, August 26, 2026 |
| April 1, 2026 | David Elkins V. EVP, Chief Financial Officer | Sale | 30,000 | $1.9M | Form 4, April 2, 2026 |
| September 2, 2025 | David Elkins V. EVP, Chief Financial Officer | Sale | 56,000 | $2.7M | Form 4, September 3, 2025 |
| August 2, 2025 | Bartie Wendy Short EVP, Corporate Affairs | Sale | 378 | $17K | Form 4, August 5, 2025 |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-08
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-05
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-18
- Item 8.01 Other events
- 8-K filed 2025-11-10
- Item 8.01 Other events
- 8-K filed 2025-11-03
- Item 8.01 Other events
- 8-K filed 2025-10-30
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Bristol Myers Squibb Co
- What does Bristol Myers Squibb Co do?
- In its own words, from Item 1 of its 10-K: "Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger."
- What is Bristol Myers Squibb Co's revenue?
- $48.2B for the fiscal year ending December 31, 2025, from its 10-K filed February 11, 2026.
- Is Bristol Myers Squibb Co profitable?
- Bristol Myers Squibb Co reported net income of $7.1B for the fiscal year ending December 31, 2025.
- How many employees does Bristol Myers Squibb Co have?
- About 32,500 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Bristol Myers Squibb Co?
- Christopher S. Boerner, Chief Executive Officer, as named in a 4 filed March 12, 2026.
- Who is the CFO of Bristol Myers Squibb Co?
- David Elkins V., EVP, Chief Financial Officer, as named in a 4 filed April 2, 2026.
- Where is Bristol Myers Squibb Co headquartered?
- Princeton, NJ.
- What is Bristol Myers Squibb Co's stock ticker?
- BMY, CELG-RI on NYSE.
- What industry is Bristol Myers Squibb Co in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Bristol Myers Squibb Co's website?
- bms.com. Investor relations: https://www.bms.com/investors.html.
- When does Bristol Myers Squibb Co report earnings next?
- January 28, 2027. Source: estimate_8k_pattern.
- Is Bristol Myers Squibb Co a public company?
- Yes. Bristol Myers Squibb Co files with the SEC under CIK 0000014272 and trades as BMY.
- Who audits Bristol Myers Squibb Co?
- Deloitte & Touche LLP, Morristown, New Jersey, as named in its latest annual report (10-K).
- How many shares of Bristol Myers Squibb Co are outstanding?
- 2.04 billion shares as of October 21, 2026, from its 10-Q filed October 29, 2026.
- What is Bristol Myers Squibb Co's public float?
- $94.2B as of June 30, 2025, as reported on the cover of its 10-K filed February 11, 2026.
- When is Bristol Myers Squibb Co's annual shareholder meeting?
- May 5, 2026, per its proxy statement (DEF 14A) filed March 25, 2026.
- Have Bristol Myers Squibb Co insiders traded stock recently?
- Since August 2, 2025, officers and directors reported 6 open-market sales worth about $5.2M and 0 purchases on Forms 4 and 5. The most recent: Julia A. Haller (Director) sold 3,800 shares on November 5, 2026.